^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    INHBA rs2237432

    i
    Other names: INHBA, EDF, FRP
    Entrez ID:
    3624
    Related biomarkers:
    Expression
    4years
    A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. (PubMed, PLoS One)
    Associations between twelve single nucleotide polymorphisms in 8 genes (INHBA, MSTN, ALK4, TGFBR1, ALK7, ACVR2B, SMAD2, FOXO3) and clinical outcome were evaluated in mCRC patients of three cohorts: a discovery cohort of 150 patients receiving regorafenib, a validation cohort of 80 patients receiving regorafenib and a control cohort of 128 receiving TAS-102. This was the first study evaluating the associations between polymorphisms in cachexia-associated genes and outcomes in refractory mCRC patients treated with regorafenib. Further studies should be conducted to confirm these associations.
    Clinical • Retrospective data • Journal
    |
    FOXO3 (Forkhead box O3)
    |
    FOXO3 rs12212067 • INHBA rs2237432
    |
    Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)